Clinical trials: Gastrointestinal Reflux
Gastroesophageal Reflux Disease (GERD)
Rabeprazole Extended-Release, 50 mg, Versus Esomeprazole, 40 mg, for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)
The purpose of this study is to investigate the efficacy (ie, healing and symptom relief) and safety of Rabeprazole Extended-Release (RAB ER) 50 mg versus Esomeprazole (ESO) 40 mg for the treatment of moderate to severe erosive…
- Trial name
- NCT00658775
- Testing
- Rabeprazole sodium, Esomeprazole
- Where
- 83 sites in United States, Argentina and 12 more
- Volunteers
- 1,069 people
- Sponsor
- Eisai Inc.
GERD
Esomeprazole for Prevention of Upper Gastrointestinal Symptoms Associated With Continuous Use of NSAIDs
This study was a multicentre, double-blind, randomised, placebo-controlled parallel group study consisting of 4 visits over a period of 6 months.
- Trial name
- NCT00241514
- Testing
- Esomeprazole
- Where
- 113 sites in United States, Belgium and 4 more
- Volunteers
- 334 people
- Sponsor
- AstraZeneca
Reflux Oesophagitis
Safety, Tolerability and Pharmacokinetics of Single Rising Doses of YF476, a Gastrin Antagonist, in Healthy Men
The objectives of the study were: To assess the safety, tolerability and pharmacokinetics of YF476 in healthy volunteers. To select a dose or doses of YF476 for detailed pharmacodynamic studies in healthy volunteers.
- Trial name
- NCT01538784
- Testing
- YF476
- Where
- United Kingdom
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Trio Medicines Ltd.
Reflux Esophagitis
Reflux Esophagitis Phase III Study (Initial Treatment)
This study is to evaluate the efficacy of esomeprazole 20 mg once daily and 40 mg once daily for 8 weeks on healing of Reflux Esophagitis in patients with reflux esophagitis in comparison with omeprazole 20 mg once daily by…
- Trial name
- NCT00633932
- Testing
- Esomeprazole, Omeprazole
- Where
- 41 sites in Japan
- Volunteers
- 602 people
- Sponsor
- AstraZeneca
Gastroesophageal Reflux
ADX10059 as an add-on Therapy to Proton Pump Inhibitors (PPIs) in Patients With Gastroesophageal Reflux (GERD)
The purpose of this study is to evaluate the effect of ADX10059 in patients with gastroesophageal reflux disease who are partial responders to proton pump inhibitors
- Trial name
- NCT00810485
- Testing
- ADX10059
- Where
- 40 sites in United States, France and 3 more
- Volunteers
- 298 people
- Sponsor
- Addex Pharma S.A.
Upper GIT Symptoms
Prevalence of Gastroesophageal Reflux Disease (GERD) in Patients With Upper Gastrointestinal Track (GIT) Symptoms in Thailand
This is a prospective , epidemiological, multi-centre, phase IV study, approximately 5,000 patients who suffer with upper gastrointestinal tract symptoms. Each patient will be assessed for GERD with GerdQ Thai Version.
- Trial name
- GerdQ (NCT00999063)
- Where
- 25 sites in Thailand
- Volunteers
- 4,108 people
- Sponsor
- AstraZeneca
Gastroesophageal Reflux Disease
Comparison of the Effect of Rabeprazole 50 mg DDR Capsules and 20 mg Enteric-coated Tablets
It is planned to compare the efficacy and safety of rabeprazole 50 mg DDR (dual delayed release) capsules versus rabeprazole 20 mg enteric coated tablets administered once daily in patients with Gastroesophageal Reflux Disease…
- Trial name
- NCT03037606
- Testing
- Rabelis DDR 50 mg Capsules, Pariet 20 mg Enteric Coated Tablets
- Where
- Turkey (Türkiye)
- Volunteers
- 48 people
- Sponsor
- Neutec Ar-Ge San ve Tic A.Ş
Gastroesophageal Reflux
Non-interventional Study to Evaluate the Change in Symptoms Scores and Treatment Response After 4 Weeks of Proton-Pump Inhibitors (PPI) Treatment
The primary objective of the study is to describe the change in GerdQ sum scores, after a 4-week period of systematic treatment with PPIs(using GerdQ questionnaire).
- Trial name
- NCT01103804
- Where
- 19 sites in Romania
- Volunteers
- 952 people
- Sponsor
- AstraZeneca
GERD
Efficacy and Saafety of Omez Iin Patients With H.Pylori Associated Diseases
Comparison of efficacy of H.pylori eradication during first line therapy using standard or high doses of omeprazole administered twice daily in combination with amoxicillin and clarithromycin for 10 days.
- Trial name
- Omez-RU2013 (NCT02922699)
- Testing
- OMEZ 40, OMEZ 80
- Volunteers
- 120 people
- Sponsor
- Dr. Reddy's Laboratories Limited
Oesophageal Reflux, Gastric Reflux
Efficacy and Speed of Action of a Product to Control Gastric Hydration and Gastroesophageal Reflux
A Randomised, Placebo-Controlled Clinical Trial off the Efficacy and Rapidity of Action of a Product Containing Sodium Alginate, Calcium and Magnesium Salts, Hyaluronic Acid and Aloe Vera to Control Oesophageal-Gastric pH and…
- Conditions
- Oesophageal Reflux, Gastric Reflux, Hyperactivity; Stomach
- Trial name
- AQUAA (NCT05060744)
- Testing
- Antacid, Control
- Where
- Spain
- Volunteers
- 50 people
- Sponsor
- Uriach Consumer Healthcare
Gastroesophageal Reflux Disease (GERD)
A Study of the Safety and Effectiveness of Rabeprazole for the Treatment of Gastroesophageal Reflux Disease (GERD) in Pediatric Patients
The purpose of the study is to access the effectiveness and safety of oral rabeprazole in the treatment of acid-related disorders in pediatric patients, focusing specifically on the manifestation of GERD (symptomatic and erosive…
- Trial name
- NCT00787891
- Testing
- rabeprazole
- Volunteers
- 127 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Gastroesophageal Reflux
Verification Study on Lafutidine in Mild Reflux Oesophagitis - Double Blind Controlled Study With Famotidine -
The purpose of the study is to verify superiority of the lafutidine group over the placebo group and non-inferiority to the famotidine group in terms of endoscopic healing rate of the patients with mild reflux oesophagitis.
- Trial name
- NCT00229424
- Testing
- Lafutidine, Famotidine
- Where
- Japan
- Volunteers
- 325 people
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
GERD
Clinical Trial to Evaluate the Safety and Efficacy of JP-1366 in Patients With Erosive Gastroesophageal Reflux Disease
Clinical trial to evaluate the safety and efficacy of JP-1366 in patients with erosive gastroesophageal reflux disease
- Trial name
- NCT04282954
- Testing
- JP-1366, Esomeprazole 40mg
- Where
- South Korea
- Volunteers
- 188 people
- Sponsor
- Onconic Therapeutics Inc.
Acid Reflux, Gastro Oesophageal Reflux Disease
A Three-Period Study to Investigate the Relative Bioavailability and Pharmacodynamic Profiles of a Zegerid 20mg Capsule, Zegerid 20mg Powder for Oral Suspension and Losec 20mg Capsule in Healthy Adult Volunteers Under Fasting Conditions
The purpose of this study is to assess the effectiveness of Zegerid 20mg capsules and powder and Losec 20mg capsules in healthy volunteers under fasting conditions.
- Trial name
- NCT01710995
- Testing
- Zegerid, Losec
- Where
- United Kingdom
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Norgine
Non-erosive Reflux Disease
A Study to Investigate the Pharmacodynamic Effect After Four-week Omeprazole Treatment of Non-erosive Reflux Disease in a Japanese Population
The purpose of this study is to investigate the pharmacodynamic effect of omeprazole n a Japanese non-erosive reflux disease population
- Trial name
- NCT00259051
- Testing
- Omeprazole
- Where
- 13 sites in Japan
- Volunteers
- 40 people
- Sponsor
- AstraZeneca
Reflux Esophagitis
The Efficacy and Safety of DWP14012 in Chinese Patients With Reflux Esophagitis
To evaluate the efficacy, safety, and cost-effectiveness of DWP14012 40 mg compared to esomeprazole magnesium enteric-coated tablets for the treatment of reflux esophagitis.
- Trial name
- NCT05813561
- Testing
- DWP14012
- Where
- China
- Volunteers
- 332 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Gastroesophageal Reflux Disease, Gastro-oesophageal Reflux
Observational Study (This Means That no Drug is Tested) in Patients Suffering of Gastroesophageal Reflux Disease.
The purpose of this observational study (this means that no drug is being tested in this study) is to obtain updated and detailed information about the Gastroesophageal Reflux Disease (GERD) specificities in European patients.
- Conditions
- Gastroesophageal Reflux Disease, Gastro-oesophageal Reflux, Gastro-Esophageal Reflux, Esophageal Reflux
- Trial name
- PROFILE (NCT01601379)
- Volunteers
- 7,964 people
- Sponsor
- Janssen-Cilag International NV
Gastroesophageal Reflux Disease, Dyspepsia
Compound Sodium Alginate Double Action Chewable Tablet Symptomatic Relief Study
This study is being conducted to provide evidence that Compound Sodium Alginate Double Action Chewable Tablets are effective in managing the symptoms of heartburn, acid regurgitation and dyspepsia in patients with…
- Trial name
- NCT01869491
- Testing
- Compound Sodium Alginate Double Action Chewable Tablets
- Where
- 2 sites in China
- Volunteers
- 1,107 people
- Sponsor
- Reckitt Benckiser Healthcare (UK) Limited
Gastroesophageal Reflux
Phase III Study Comparing Zegerid® With Losec® for the Relief of Heartburn Associated With Gastroesophageal Reflux Disease
Heartburn is the main symptom of Gastroesophageal Reflux Disease (GERD), which, accompanied by acid regurgitation and other symptoms, has a substantial negative impact on a patients' quality of life.
- Trial name
- NCT01493089
- Testing
- Zegerid, Losec
- Where
- Poland
- Volunteers
- 239 people
- Sponsor
- Norgine
Gastroesophageal Reflux Disease
PREA, PK And Safety PASS Study Of IV Pantoprazole In Pediatric Subjects
The purpose of this study is to characterize the pharmacokinetics (PK) and safety of intravenous (IV) pantoprazole in patients 1 to 16 years old who are candidates for acid suppression therapy.
- Trial name
- NCT02401035
- Testing
- IV pantoprazole
- Where
- 19 sites in United States, Argentina and 7 more
- Volunteers
- 19 people
- Sponsor
- Pfizer